On November 16, 2026, MapLight Therapeutics, Inc. (the “Company”) entered into a Sales Agreement (the “Agreement”) with Leerink Partners LLC (the “Agent”), pursuant to which the Company from time to time may offer and sell shares (the “ATM Shares”) of its voting common stock, par value $0.0001 per share (“Common Stock”), through or to the Agent (the “ATM Offering”). The ATM Shares will be offered and sold pursuant to a Registration Statement on Form S-3 filed by the Company on November 16, 2026 (the “Registration Statement”) and the prospectus related to the ATM Offering that forms a part of such Registration Statement (the “ATM Prospectus”). Pursuant to the ATM Prospectus, the Company may sell Common Stock having an aggregate offering price of up to $100,000,000. Subject to the terms and conditions of the Agreement, the Agent will use its commercially reasonable efforts to sell the ATM Shares from time to time, based upon the Company’s instructions. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a commission of up to 3.0% of the aggregate gross sales price per share sold under the Agreement.
|
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing circuit-specific pharmacotherapies for central nervous system disorders. The company focuses on neuropsychiatric conditions, including schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder. Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, currently in Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. A second candidate, ML-004, is a 5-HT1B/1D agonist being evaluated for social communication deficits in autism spectrum disorder. The company also maintains preclinical programs for hyperactivity and agitation-related disorders, including ML-009, ML-055, and ML-021. MapLight utilizes a discovery platform that combines technologies such as optogenetics, transcriptomics, and STARmap to identify neural circuits linked to disease. The company was founded by leaders in psychiatry and neuroscience research to address the lack of targeted treatments for debilitating brain disorders. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage maplightrx.com |
| Sector Healthcare | IR page ir.maplightrx.com | |
|
Tags
neuropsychiatric disorders, schizophrenia, alzheimer's disease psychosis, autism spectrum disorder, muscarinic receptor agonists, circuit-specific pharmacotherapies, clinical-stage, central nervous system, ML-007C-MA, ML-007, ML-004, ML-009, ML-055, ML-021, ZEPHYR, VISTA, IRIS
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 447.586M |
| Market cap (USD) | $ 447.586M |
| P/E | -0.43 |
| PEG | — |
| P/BV | 1.00 |
| P/S | — |
| P/OCF | -3.24 |
| P/FCF | -3.23 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -56.2% |
| ROI | -38.7% |
| ROIC | -30.4% |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | — |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | — |
| Buying back stock | No |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 16 |
| Quality score | -50.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2024 | Dec 2025 |
|---|---|---|
| Balance sheet detail | ||
| Lease liabilities (USD) | 6.58M | 5.8M |
| Cash and deposits (USD) | 38.3M | 46.7M |
| Right-of-use assets (USD) | 6.35M | 5.49M |
| Cash flow detail | ||
| Operating cash flow (USD) | -78.8M | -138M |
| Purchases of property, plant and equipment (USD) | -770,000 | -473,000 |
| Change in payables (cash effect) (USD) | -1.35M | 1.38M |
| Share-based compensation (USD) | 1.08M | 36M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -79.6M | -139M |
| Income detail | ||
| Research and development expense (USD) | 68.5M | 138M |
| Total comprehensive income (USD) | -77.4M | -162M |
| Comprehensive income to owners (USD) | -77.4M | -162M |
| Reported | Mar 26, 2026 | Mar 26, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpMaterial events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Press releases from the company's own website, newest first.
Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027
Enrollment ongoing in Phase 2 VISTA trial in Alzheimer’s disease psychosis, with topline results now expected in 2028; ML-007C-MA holds FDA Fast Track designation in ADP
Ended the quarter with $463.4 million in cash, cash equivalents and investments, expected to fund operations through key clinical readouts and through 2028
SAN FRANCISCO and BOSTON, November 16, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.
“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market,” said Chris Kroeger, Co-Founder and Chief Executive Officer of MapLight.
Oct 6, 2026
Award honors foundational discoveries in optogenetics and circuit mapping
These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery
SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning light-gated ion channels and optogenetics.
The Nobel Assembly recognized optogenetics for transforming scientists’ ability to study how nerve cells shape memories, feelings and behaviors in the living brain, laying the foundation for a new era in neuroscience. Over the past two decades, optogenetics has fundamentally advanced the understanding of the biological basis of behavior, cognition and neuropsychiatric disease.
Dr. Deisseroth’s academic breakthroughs enabled scientists to investigate causal relationships between specific neural circuits and behavior and inspired the founding of MapLight in 2018. MapLight translates insights from circuit neuroscience into a precision approach to drug discovery, using optogenetics and related tools to identify specific cell types and molecular targets linked to psychiatric and neurodevelopmental symptoms. The Company then develops oral small-molecule candidates designed to modulate disease-relevant circuit activity and provide potential therapeutic relief.
This approach underpins the translation of circuit biology into a diverse pipeline of early- and clinical-stage product candidates. The Phase 2 ZEPHYR study of ML-007C-MA, which evolved from optogenetic and other preclinical work at MapLight, recently met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in schizophrenia symptoms. Based on these results, MapLight announced its intention to engage with the FDA in an End-of-Phase 2 (EOP2) meeting and subsequently initiate a Phase 3 study in schizophrenia. Similarly, preclinical work leveraging optogenetics in models of autism informed the design and conduct of the Phase 2 IRIS study. Based on these results, MapLight announced its intention to engage with the FDA in an EOP2 meeting to discuss a planned Phase 3 program in irritability associated with autism.
“Optogenetics began as a way to ask a basic question: how does electrical activity in specific cells give rise to human behavior and emotion?” said Dr. Deisseroth. “Neuroscience has long needed a better understanding of the functional biology of neural circuits and the relationship between circuit dysfunction and disease. I am deeply grateful to the institutions, trainees, and colleagues that have enabled and supported my work over the years, and to Peter Hegemann and Georg Nagel for their foundational contributions. As a practicing psychiatrist, seeing these basic biological discoveries move from the lab into human clinical trials is the ultimate realization of this work.”
“On behalf of everyone at MapLight, congratulations to Karl on this monumental achievement,” said Christopher Kroeger, M.D., Chief Executive Officer of MapLight. “The Nobel recognition of Karl’s academic work is a triumph for basic science and underscores the transformative impact of understanding the brain at the circuit level. Karl’s Nobel work inspired MapLight’s founding premise: that understanding the causal relationship between neural circuits and behavior can enable a more precise approach to developing medicines for complex CNS disorders. We are incredibly proud to celebrate this extraordinary honor with Karl and to continue advancing the mission that his work inspired.”
Additional information about the 2026 Nobel Prize in Physiology or Medicine and the discoveries recognized by the Nobel Assembly is available in its official announcement.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
Company History
Name and ticker changes, and re-registrations under a new regulatory id. When a ticker stopped being used is not recorded, so former tickers are undated.
| Date | Change | Detail |
|---|---|---|
| Sep 4, 2019 | Renamed | Alvarado Therapeutics, Inc. → MAPLIGHT THERAPEUTICS, INC. |
ETFs Holding MapLight Therapeutics, Inc.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.



